Abstract-This paper presents so-called radiation effectiveness factors that are intended to represent the biological effectiveness of different radiation types, relative to high-energy 60 Co gamma rays, for the purpose of estimating cancer risks and probability of causation of radiogenic cancers in identified individuals. Radiation effectiveness factors are expressed as subjective probability distributions to represent uncertainty that arises from uncertainties in estimates of relative biological effectiveness obtained from radiobiological studies of stochastic endpoints, limited data on biological effectiveness obtained from human epidemiological studies, and other judgments involved in evaluating the applicability of available information to induction of cancers in humans. Primarily on the basis of reviews and evaluations of available data by experts, probability distributions of radiation effectiveness factors are developed for the following radiation types: neutrons of energy less than 10 keV, 10 -100 keV, 0.1-2 MeV (including fission neutrons), 2-20 MeV, and greater than 20 MeV; alpha particles of any energy emitted by radionuclides; photons of energy 30 -250 keV and less than 30 keV; and electrons of energy less than 15 keV. Photons of energy greater than 250 keV and electrons of energy greater than 15 keV are assumed to have the same biological effectiveness as reference 60 Co gamma rays and are assigned a radiation effectiveness factor of unity, without uncertainty. For neutrons and alpha particles, separate probability distributions of radiation effectiveness factors are developed for solid tumors and leukemias, and small corrections to represent an inverse dose-rate effect are applied to those distributions in cases of chronic exposure. A radiation effectiveness factor different from unity for 15-60 keV electrons is discussed but is not adopted due to a lack of relevant radiobiological data. Radiation effectiveness factors presented in this paper are incorporated in the Interactive RadioEpide- 
INTRODUCTION
THIS PAPER presents so-called radiation effectiveness factors (REFs) that are intended to represent the biological effectiveness of different types of ionizing radiation for the purpose of estimating cancer risks and probability of causation of radiogenic cancers in identified individuals. † An REF is a dimensionless factor used to modify an estimate of average absorbed dose from a given radiation type in an organ or tissue of concern in an identified individual to obtain a biologically significant dose on which the risk of induction of cancer in that organ or tissue is assumed to depend.
‡ The different radiation types for which REFs are presented include photons, electrons, alpha particles emitted by radionuclides, and neutrons. The reference radiation with a defined REF of unity is assumed to be high-energy 60 Co gamma rays at high doses and high dose rates. That choice is appropriate when estimates of cancer risks in humans are based primarily on studies of Japanese atomic-bomb survivors who mainly received acute doses of high-energy gamma rays and many studies of the biological effectiveness of different radiation types have used 60 Co gamma rays as the reference radiation.
REFs for induction of cancers in humans developed in this work are expressed as subjective probability distributions to represent their uncertainty. Probability distributions of REFs take into account uncertainties in estimates of relative biological effectiveness (RBE) for stochastic endpoints, limited data on biological effectiveness obtained from human epidemiological studies, and other judgments involved in evaluating the applicability of available information to induction of cancers in humans.
Probability distributions of REFs presented in this paper are incorporated in the Interactive RadioEpidemiological Program (IREP) and were developed for use by The National Institute for Occupational Safety and Health (NIOSH) and the U.S. Department of Labor in evaluating claims for compensation for radiogenic cancers by workers at U.S. Department of Energy (DOE) facilities. Methods used in IREP to estimate probability of causation of radiogenic cancers are documented in reports by NIOSH (2002) and the National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) (Land et al. 2003) .
The work described in this paper is based in large part on reviews and evaluations of radiobiological studies and other information by experts. Additional information in the primary literature is used to a lesser extent. What is original in this work is that it involves a comprehensive assessment of uncertainties in data on biological effectiveness of relevance to estimating cancer risks in humans from exposure to many radiation types.
Development of probability distributions of REFs must rely to a significant extent on subjective scientific judgment. The most important judgment is an assumption that RBEs obtained from studies of a number of stochastic endpoints in a variety of biological systems are applicable to induction of cancers in humans. Scientific judgment also has been applied by experts in reviewing and evaluating published studies and in drawing conclusions from their reviews. Finally, we have applied our own scientific judgments in developing probability distributions of REFs, and we recognize that other knowledgeable individuals could reach different conclusions from the same body of information.
A concern that arises in this work is the extent to which REFs should be consistent with assumptions about biological effectiveness used in radiation protection. In radiation protection, quantities analogous to an REF include the effective quality factor, Q (ICRP 1977 (ICRP , 1985 ICRU 1986; NCRP 1987) and the radiation weighting factor, w R (ICRP 1991; NCRP 1993) . Point values of w R currently used in radiation protection are given in Table  1 , and the energy dependence of Q for photons calculated by the ICRU (1986) , which is used in this work, is shown in Fig. 1 .
Although consistency between REFs and analogous radiation protection quantities seems desirable, two other considerations were of overriding importance to our work. First, prescribed point values of w R and Q do not reveal the full state of knowledge of the values, including uncertainties in RBEs on which they are based and other judgments. However, uncertainties in biological effectiveness must be taken into account in estimating risk and probability of causation for the purpose of evaluating claims by individuals that their cancers were caused by radiation exposure when there are legal requirements to give claimants the benefit of the doubt.
§ Second, for some radiation types, point values of radiation protection quantities are not consistent with a substantial body of radiobiological data. For example, although there was clear evidence that the biological effectiveness of orthovoltage (180 -250 kVp) x rays at low doses is approximately twice that of high-energy 60 Co gamma rays (ICRU 1986) , that difference is not incorporated in current recommendations on w R for photons (see Table  1 ). Similarly, current recommendations on w R for electrons do not incorporate clear evidence from many § The compensation program for DOE workers who develop cancers requires that claims be evaluated using an upper 99% confidence limit of probability of causation that is estimated by accounting for all uncertainties (DHHS 2002 ). The same upper confidence limit of probability of causation is used by the U.S. Department of Veterans Affairs (DVA) to evaluate claims for compensation for cancers by members of military services who participated in the atmospheric nuclear-weapons testing program during the period 1945-1962 (Otchin 2001 ICRP (1991) and NCRP (1993) . b Auger electrons emitted in decay of radionuclides incorporated into DNA are excluded.
studies of an increased biological effectiveness of lowenergy beta particles emitted in 3 H decay.** On the basis of these considerations, we did not assume a priori that point values of w R or Q used in radiation protection provide best estimates of REFs for the purpose of estimating cancer risks and probability of causation of cancers in identified individuals.
The main emphasis of this paper is to present summaries of RBEs and other data used in our analysis and to discuss the subjective scientific judgments we used to develop probability distributions of REFs for the radiation types of concern on the basis of those data. Needs for further work to address possible deficiencies in our analysis also are discussed. REFs presented in this paper represent analyses that were completed by June 2002 (Kocher et al. 2002) . Other information on biological effectiveness obtained from more recent literature is discussed, but such information has not been incorporated in assumed probability distributions of REFs.
USE OF REFS IN CALCULATING PROBABILITY OF CAUSATION
To assist in understanding the REFs developed in this work, we first describe how they are used to estimate cancer risk and probability of causation associated with a given absorbed dose in an organ or tissue in which a cancer has occurred in an identified individual. In the methodology incorporated in IREP (Land et al. 2003) , separate models are used to estimate risks of solid tumors and leukemias on the basis of assumptions that the dose-response in Japanese atomic-bomb survivors who mainly received acute doses of high-energy gamma rays is linear for all solid tumors but linear-quadratic for leukemias, and that those dose-response relationships can be extrapolated to lower doses and dose rates. It also is assumed that, for any cancer type, the dose-response for neutrons and alpha particles is linear at any dose and dose rate, and that for a particular cancer type and conditions of exposure (acute or chronic), the dose-response for photons and electrons has the same form (i.e., linear or linear-quadratic). Thus, except in cases of exposure to alpha particles emitted by short-lived decay products of radon in air, when risks of lung cancer are estimated on the basis of estimates of exposure without use of absorbed dose and an REF (Land et al. 2003) , cancer risks are estimated in IREP as follows:
Solid tumors:
Leukemia:
In these equations:
• ᑬ is the excess relative risk (ERR) of a given cancer associated with a given absorbed dose, D, of a particular radiation type; • R ␥,H is the risk coefficient (ERR per Gy) for a given solid tumor at high acute doses of high-energy gamma (␥) rays; † † • the subscript L or H in an REF indicates that it is derived from estimates of RBE at low doses and low ** In early recommendations of the ICRP (1960), absorbed dose from 3 H beta particles was modified by a factor N ϭ 1.7 to account for an increased biological effectiveness, but this modifying factor was not retained in later recommendations (ICRP 1977 (ICRP , 1991 . † † In this work, a dose is considered "high" if a statistically significant increase in cancers has been observed at that dose in epidemiological studies, especially in studies of Japanese atomicbomb survivors. Thus, a "high" dose is on the order of 0.1 Gy or higher.
Fig. 1.
Effective quality factor vs. photon energy under conditions of charged-particle equilibrium (ICRU 1986, Fig. 3) calculated based on defined relationship between quality factor and lineal energy in 1-m diameter sphere of tissue-equivalent material (ICRU 1986, Fig. 2) . Values are normalized to unity at energies of orthovoltage (180 -250) kVp x rays; energies of 60 Co gamma rays are at right end of curve.
dose rates or at high doses and high dose rates of reference high-energy gamma rays, respectively; • DDREF ␥ is the dose and dose-rate effectiveness factor for photons, which takes into account that for solid tumors with an assumed linear dose-response, the ERR per Gy at low doses or low dose rates of photons may be less than the risk coefficient at high acute doses estimated from epidemiological studies; and • a and b are coefficients of the linear and quadratic terms, respectively, in the assumed linear-quadratic dose-response for leukemias under conditions of acute exposure to high-energy gamma rays.
The equation used to estimate risk depends on the radiation type and cancer of concern. For solid tumors, eqn (1) is used in cases of exposure to photons, electrons, or alpha particles, and eqn (2) is used in cases of exposure to neutrons; the different approach to estimating risks of solid tumors from exposure to neutrons is discussed in the next section. For leukemias, eqn (3) is used in cases of acute exposure to photons or electrons, and eqn (4) is used in cases of chronic exposure to photons or electrons and any exposures to alpha particles or neutrons; for this type of cancer, the dose-response for photons and electrons is assumed to be linear-quadratic in cases of acute exposure but linear in cases of chronic exposure.
‡ ‡ The coefficients a and b for leukemias and R ␥,H for solid tumors also incorporate assumptions about the dependence of radiation risk on sex, age at exposure, age at time of diagnosis of disease (attained age), and, for leukemias only, time since exposure (Land et al. 2003) .
The dose and dose-rate effectiveness factor for photons (DDREF ␥ ) is used to estimate risks of solid tumors when an REF for the radiation type of concern is derived from estimates of RBE at low doses and low dose rates. DDREF ␥ renormalizes risk coefficients at high acute doses of high-energy gamma rays, R ␥,H , which are obtained mainly from studies of Japanese atomic-bomb survivors, to give risk coefficients at low doses or dose rates that are compatible with an REF L . A DDREF ␥ is not used to estimate risks of leukemias. However, a similar effect is obtained by assuming that the dose-response for acute exposure to high-energy gamma rays is linearquadratic, and that the dose-response for chronic exposure to those radiations is linear and is defined by the linear term in the assumed dose-response for acute exposure. In the methodology incorporated in IREP (Land et al. 2003) , DDREF ␥ is an uncertain parameter that is applied at acute doses less than 0.2 Gy and in all cases of chronic exposure, and the same assumptions about DDREF are used to estimate risks from exposure to electrons. A DDREF is not applied to the dose-response for neutrons or alpha particles.
Once the excess relative risk, ERR, associated with a given absorbed dose and cancer of concern is estimated using one of the equations given above, probability of causation (PC) is calculated as PC ϭ ERR/(ERR ϩ 1). In the methodology incorporated in IREP (Land et al. 2003) , a probability distribution of PC, which is intended to represent its uncertainty, is calculated on the basis of assumed probability distributions of all parameters, including the absorbed dose, the risk coefficient R ␥,H for the particular solid tumor or the coefficients a and b for leukemias at high acute doses of gamma rays, DDREF ␥ if it is used, and the appropriate REF. § §
PROBABILITY DISTRIBUTIONS OF REFS FOR NEUTRONS
Approaches to estimating REFs for neutrons RBEs for neutrons have been estimated in many radiobiological studies involving different organisms, stochastic endpoints, and doses and dose rates. Most studies used fission neutrons or other neutrons of similar energies; relatively few studies used neutrons of lower or higher energies. Reviews and evaluations of RBEs for neutrons considered in this work were presented by the ICRU (1986) , NCRP (1990) , and Edwards (1997 Edwards ( , 1999 .
In most studies of neutrons, doses and dose rates were substantially above levels of concern in routine exposures of workers and the public. Therefore, since RBEs for neutrons generally increase with decreasing dose [e.g., see ICRU (1986) , Fig. C-2] , an important focus of radiobiological studies and reviews and evaluations of those studies by experts has been to estimate RBEs at low doses and dose rates. Such RBEs, which often are denoted by RBE M , where M indicates a maximum value, are obtained by extrapolation of data on dose-response for neutrons and the reference radiation at higher doses and dose rates.
From an evaluation of estimates of RBE M obtained from studies deemed relevant to estimating cancer risks in humans, a representative probability distribution of REF at low doses and low dose rates, which we denote by REF L , could be developed. Given that estimates of RBE M for fission neutrons and various stochastic endpoints range from about 3 to more than 100 (ICRU 1986; NCRP 1990 ), a representative probability distribution of REF L for those radiations would span a wide range of ‡ ‡ An exposure is considered chronic if the absorbed dose rate, averaged over a period of a few hours, is less than 6 mGy h Ϫ1 or the exposure is protracted over a period of more than 1 d (Land et al. 2003) . § § Land et al. (2003) refers to probability of causation as "assigned share" (AS) to indicate that it is estimated for identified individuals on the basis of observed cancer risks in populations.
values. As described below, however, we have taken a different approach to estimating REFs for neutrons for use in estimating risks of solid tumors. In most studies, the dose-response for neutrons is linear at doses of a few Gy or less. However, the dose-response for low-LET reference radiations usually is linear-quadratic (ICRU 1986; NCRP 1990) . In addition, there are substantial variations in responses at low doses of the reference radiations relative to responses at high doses, which result in a wide range of DDREFs for those radiations (CIRRPC 1995; Edwards 1997 Edwards , 1999 .*** Thus, the variability in RBE M for fission neutrons obtained from different studies is due in part to variations in doseresponse for the reference radiations, with high values of RBE M tending to be associated with high DDREFs for the reference radiations and low values with low DDREFs. Since DDREFs embodied in estimates of RBE M generally are not the same as a value of DDREF ␥ that might be used to adjust observed cancer risks in humans at high acute doses of high-energy gamma rays to estimate risks at low doses or dose rates, a probability distribution of REF L developed on the basis of the variability in RBE M may not provide the best representation of the biological effectiveness of low doses of neutrons in humans relative to high-energy gamma rays at low doses or dose rates.
Difficulties in developing a representative probability distribution of REF L for neutrons on the basis of highly variable estimates of RBE M can be addressed using an alternative approach (CIRRPC 1995; Edwards 1997 Edwards , 1999 , which is based on the view that assumed REFs for neutrons should be consistent with data used to estimate cancer risks from exposure to photons. That is, the most appropriate REFs are values that represent RBEs at high acute doses of reference high-energy gamma rays because that was the condition of exposure of Japanese atomic-bomb survivors in which excess cancers have been observed and most estimates of cancer risks are obtained. We denote RBEs at high acute doses of high-energy gamma rays by RBE H and the associated REFs by REF H . If DDREF for neutrons is assumed to be unity on the basis of the oft-observed linearity in doseresponse at doses of a few Gy or less, a probability distribution of REF H that represents data on RBE H can be used to estimate cancer risks at any dose and dose rate of neutrons [e.g., using the model in eqn (2)]. Thus, estimates of cancer risk from exposure to neutrons can be based directly on estimates of RBE H , rather than extrapolated values at low doses and dose rates, RBE L , without the need to apply an uncertain DDREF ␥ to the risk coefficient at high acute doses of reference highenergy gamma radiation.
In the approach described above, there still is considerable variability in estimates of RBE H , due to the variety of biological systems and stochastic endpoints studied and the dependence of RBE on dose when the dose-response for the reference radiation is non-linear. However, as indicated by data discussed in the following section, the variability in RBE H for fission neutrons is considerably less than the variability in RBE M , due to the reduced influence at high doses of variations in DDREFs for the reference radiations in different studies. Therefore, the uncertainty in a representative REF H to be used in estimating cancer risks in humans should be substantially less than the uncertainty in a representative REF L .
We also note that estimates of cancer risk at low doses and dose rates of neutrons obtained using the alternative approach represented by the model in eqn (2) would be the same as risks estimated using the conventional approach represented by the model in eqn (1) if DDREFs for the reference radiations embodied in estimates of RBE M were the same as the value of DDREF ␥ used to adjust observed risks at high acute doses of high-energy gamma rays in humans to estimate risks at low doses and dose rates. Again, the advantage of the approach in eqn (2) is that it is directly compatible with the conditions of exposure of Japanese atomic-bomb survivors who received acute doses of high-energy gamma rays.
In principle, the alternative approach represented by the model in eqn (2) could be used to estimate risks of any cancers from exposure to neutrons. However, as indicated in the previous section, that approach is used only to estimate risks of solid tumors. The approach is particularly suitable in such cases because the dose-response for gamma rays in humans is assumed to be linear (Land et al. 2003) and risk coefficients at high acute doses of gamma rays, R ␥,H , thus are defined. The conventional approach represented by the model in eqn (4), which involves probability distributions of REF L that are based on RBEs at low doses and dose rates, is used to estimate risks of leukemias. Use of eqn (4) is appropriate when the dose-response for acute exposure to gamma rays is assumed to be linear-quadratic [see eqn (3)]. If the alternative approach in eqn (2) were used to estimate risks of leukemias from exposure to neutrons, there would be additional uncertainty that arises from the dependence of risk on the choice of a reference high acute dose of gamma rays in Japanese atomic-bomb survivors.
Selection of data on RBE for fission neutrons
As noted previously, most studies of RBEs for neutrons used fission neutrons. We developed probability *** When a linear-quadratic dose-response of the form ␣D ϩ ␤D 2 is assumed, DDREF is the ratio of the linear extrapolation to zero dose at high doses, ␣ H , to the slope at low doses, ␣ L , and, thus, is a function of dose given by 1 ϩ (␤/␣)D (CIRRPC 1995; Edwards 1997 Edwards , 1999 Data on RBE for life-shortening and induction of specific cancers in mice were reviewed and analyzed by Edwards (1997 Edwards ( , 1999 . Estimated RBEs at high acute doses, RBE H , and extrapolated values at low doses and low dose rates, RBE M , for those stochastic endpoints, as obtained by Edwards, are given in Tables 2-4. † † † Those data illustrate two points noted previously. First, RBE H usually is less than RBE M , due primarily to the influence of DDREF for the low-LET reference radiation on RBE M . Second, the variability in RBE H is less than the variability in RBE M , due primarily to the reduced influence at high acute doses of differences in DDREFs for the reference radiations in the various studies. In studies summarized in Tables 2 and 3 , for example, DDREF varies from 1 to nearly 20 when estimated as the quotient of the mean value of RBE M to the mean value of RBE H .
In studies of fission neutrons, RBEs for leukemias and related diseases tend to be less than RBEs for solid tumors (NCRP 1990; Edwards 1997 Edwards , 1999 . This comparison is indicated, for example, by RBEs for specific cancers in RF/Un and RFM mice in Table 3 . On that basis, we developed separate probability distributions of REFs for solid tumors and leukemias.
REF for fission neutrons and solid tumors
Risks of solid tumors from exposure to neutrons are estimated using the model in eqn (2). The assumed probability distribution of REF H for fission neutrons was developed from estimates of RBE H for solid tumors in Tables 2-4. The relevant RBEs are those for BALB/c and B6CF1 mice in Table 2 , the various tumors and adenocarcinomas in Table 3 , and non-lymphocytic tumors in Table 4 . On the basis of those data, we assume that REF H for fission neutrons and solid tumors can be described by a lognormal probability distribution having a 95% confidence interval between 2.0 and 30. This distribution has a geometric mean (median) of 7.7 and geometric standard deviation of 2.0. A lognormal distribution was selected mainly on the basis of the variability in estimates of RBE H and the difficulty in judging a credible upper bound of possible values. Lognormal probability distributions are assumed for several other REFs.
Data obtained from studies of tumor induction in other mammals are consistent with the assumed probability distribution of REF H for fission neutrons and solid tumors. For example, Wolf et al. (2000) deduced an RBE of about 20 -25 for lethal tumors in Sprague-Dawley rats at an acute dose of fission neutrons of 0.1 Gy. In a study in which monkeys were given average doses of 6.7 Gy of x rays and 3.4 Gy of fission neutrons, Broerse et al. (1991) derived an RBE for tumor induction of about 4 -5. When this RBE is adjusted to account for a difference of about a factor of 2 in biological effectiveness of x rays and high-energy gamma rays, as discussed later, an RBE relative to high-energy gamma rays of about 8 -10 is obtained.
Fission neutrons have a continuous spectrum of energies that normally ranges from about 0.1 to 15 MeV; † † † Estimates of RBE H by Edwards (1997) incorporate a DDREF of 2 for the reference radiations and, thus, are a factor of 2 higher than values given by Edwards (1999) . Estimates uncorrected for DDREF in Edwards (1999) are the appropriate ones for use in this analysis. the most probable energy is about 0.8 MeV, and the average energy is about 2.0 MeV (Shleien et al. 1998, Table 7 .1). As described later, probability distributions of REFs that represent RBEs for fission neutrons are assumed to apply at energies of 0.1-2 MeV.
REF for fission neutrons and leukemias
Risks of leukemias and related diseases from exposure to neutrons are estimated using the model in eqn (4). The assumed probability distribution of REF L for fission neutrons was developed from estimates of RBE M in Tables 2-4. The relevant RBEs are those for RF/Un and RFM mice in Table 2 , lymphoma and leukemias in Table 3 , and lymphocytic tumors in Table 4 . On the basis of those data, we assume that REF L for fission neutrons and leukemias can be described by a lognormal probability distribution having a 95% confidence interval between 2.0 and 60. Upton et al. (1970) , Ullrich et al. (1976 Ullrich et al. ( , 1977 Ullrich et al. ( , 1979 , Ullrich (1980 Ullrich ( , 1984 , Mole and Davids (1982) , Mole et al. (1983) , Ullrich and Preston (1987) , and Coggle (1988) . b LL and UL are lower and upper 68% confidence limits on the mean, respectively, corresponding to standard error. This distribution has a geometric mean of 11 and geometric standard deviation of 2.4.
REFs at other neutron energies
Estimation of cancer risks in humans from exposure to neutrons is complicated by the apparent energy dependence of RBEs. In radiation protection, that energy dependence is represented by the radiation weighting factor in Table 1 ( ICRP 1991; NCRP 1993) , the effective quality factor calculated by the ICRU (1986, Fig. 4) , and the effective quality factor calculated previously by the NCRP (1971, Table 2 ) and ICRP (1973, Fig. 15 ) and increased by a factor of 2 (ICRP 1985; NCRP 1987) . Thus, probability distributions of REFs for fission neutrons described above apply at energies where the biological effectiveness of neutrons is the highest.
Reductions in w R by a factor of 2 or 4 at neutron energies other than 0.1-2 MeV given in Table 1 are based in part on limited data on the energy dependence of RBE M obtained from studies in animals and cell cultures. Selected data were reviewed by the NCRP (1990) and Edwards (1997 Edwards ( , 1999 . The variation of RBE M with neutron energy is illustrated by data shown in Figs. 2 and 3. Estimates of RBE M are in general agreement with the energy dependence of w R at energies of 10 -100 keV or 2-20 MeV, although there are exceptions. However, the NCRP (1990) and Edwards (1997 Edwards ( , 1999 did not identify any studies at energies less than 10 keV or greater than 20 MeV. Thus, there is considerable uncertainty in REFs that would represent the biological effectiveness of neutrons at those energies relative to fission neutrons.
Given the scarcity of data, we developed subjective probability distributions of REFs for solid tumors and leukemias at energies other than 0.1-2 MeV on the basis of the assumed probability distributions of REFs for fission neutrons and an assumption that the step-function representation of w R in Table 1 provides a general indication of the energy dependence of REFs. Thus, we assume that probability distributions of REFs for neutrons in the energy ranges other than 0.1-2 MeV given in Table 1 should have the following three properties:
1. The lower bound should be at 1.0, based on an assumption that neutrons of any energy should not be biologically less effective than high-energy gamma rays; 2. The median should be about a factor of 2 or 4 less than the geometric mean of the corresponding lognormal probability distribution for fission neutrons; and 3. The upper 97.5% confidence limit should be less than the upper confidence limit of the corresponding lognormal probability distribution for fission neutrons, but the decrease in the upper confidence limit should be less than a factor of 2 or 4 to take into account that there is substantial uncertainty in reductions in REFs compared with values for fission neutrons, due to the scarcity of data on RBE at energies other than 0.1-2 MeV. That is, the upper confidence limit relative to the median should increase compared with this ratio in the probability distributions of REFs for fission neutrons.
Many probability distributions having the properties described above can be constructed. In the interest of (Edwards 1997, Fig. 6; Edwards 1999, Fig. 6 ). Solid circles are data from Edwards et al. (1985 Edwards et al. ( , 1990 , and open squares are data from Sevan'kaev et al. (1979) . (Edwards 1997, Fig. 7) . Solid circles with error bars representing standard error are data from Miller et al. (1989) , and open squares are data from Coppola (1993) .
simplicity and convenience, we represent REFs in the energy ranges other than 0.1-2 MeV given in Table 1 by piecewise-uniform probability distributions. We assume that each probability distribution is defined by three intervals, and we assign probabilities (weights) of 30% to the first interval, 50% to the second interval, and 20% to the third interval in all cases. The width of each interval then is adjusted to obtain a distribution in which the median and upper 97.5% confidence limit approximate the desired values. Depending on the energy range of concern, the median is set at a factor of about 2 or 4 less than the median of the corresponding lognormal probability distribution for fission neutrons (i.e., at energies of 0.1-2 MeV). At energies of 10 -100 keV and 2-20 MeV, we set the upper confidence limit of the piecewiseuniform distribution at a factor of 1.7-1.8 less than the upper confidence limit of the corresponding probability distribution for fission neutrons, and we set the upper confidence limit at a factor of (1.7-1.8)
2 , or about 3, less at energies less than 10 keV or greater than 20 MeV. We believe that reducing the upper confidence limits at energies other than 0.1-2 MeV by substantially lower factors (e.g., by a factor of about 1.5 when the median is reduced by a factor of 2) would give too much weight to the uncertainty in the reduction of the median compared with the uncertainty in the corresponding REF for fission neutrons.
The assumed piecewise-uniform probability distributions of REFs for neutrons of energy other than 0.1-2 MeV having the properties described above are summarized in Table 5 . This table also gives the assumed lognormal probability distributions of REFs for fission neutrons and an enhancement factor to represent an inverse dose-rate effect described in the following section. A small weight is given to an assumption that an REF at energies of 10 -100 keV or 2-20 MeV is higher than the corresponding REF for fission neutrons (i.e., at energies of 0.1-2 MeV). That possibility is supported by data reviewed by Edwards (1997 Edwards ( , 1999 and shown in Figs. 2 and 3, by a study which indicated that the biological effectiveness of 70 keV and 350 keV neutrons was not significantly different (Miller et al. 2000) , and by a comparison of RBEs for 24 keV neutrons and fission neutrons of mean energy 200 -900 keV (Schmid et al. 2000) . A similar assumption is incorporated in REFs at energies less than 10 keV or greater than 20 MeV compared with REFs at 10 -100 keV or 2-20 MeV, although there are no supporting data.
Correction for inverse dose-rate effect for chronic exposure to neutrons
An additional consideration in estimating cancer risks is the possibility that the biological effectiveness of neutrons, and other high-LET radiations, increases with decreasing dose rate at the same dose. This phenomenon is referred to as an inverse dose-rate effect. Some studies of life-shortening and tumor induction in small mammals at high doses of fission neutrons show an enhancement in biological effectiveness by as much as a factor of about 3 when the same dose is delivered at lower dose rates (CIRRPC 1995; NCRP 1990; ICRP 1991) . However, an effect is not seen in all studies of those endpoints at high doses, and it usually is not seen at lower doses.
Although mechanisms responsible for an observed inverse dose-rate effect for fission neutrons in some studies may not apply in estimating cancer risks in humans, especially at low doses (CIRRPC 1995), we adopted a small correction to the assumed REFs for any cancer type and energy to account for the possibility of such an effect. This correction, which we refer to as an Table 5 . Probability distributions of REFs and enhancement factor for neutrons developed in this study. enhancement factor, is applied only in cases of chronic exposure and is assumed to be independent of neutron energy. On the basis of an evaluation of data on lifeshortening and tumor induction in mice by the NCRP (1990), we assume a probability distribution of the enhancement factor for neutrons that ranges from 1 to 3 and is weighted more toward lower values. Specifically, we assume the discrete probability distribution given in Table 5 , which has an arithmetic mean of 1.4. Assigning the highest weight to the value 1.0 (i.e., an assumption of no inverse dose-rate effect) takes into account that the effect is not seen in all studies at high doses and usually is not seen at low doses of interest in routine exposures of workers and the public. In cases of chronic exposure, the assumed enhancement factor is a multiplier to the appropriate probability distribution of REF for solid tumors or leukemias.
Summary and discussion of REFs for neutrons
Assumed probability distributions of REFs for neutrons and an enhancement factor to represent an inverse dose-rate effect, which is applied in cases of chronic exposure to neutrons, are given in Table 5 . In comparing probability distributions of REFs, it is important to bear in mind that REFs for solid tumors apply at high acute doses of high-energy gamma rays, whereas REFs for leukemias apply at low doses and dose rates. To provide more meaningful comparisons of REFs for the two cancer types, probability distributions of REF H for solid tumors could be increased by a factor of 2, based on the DDREF for gamma rays used in radiation protection (ICRP 1991; NCRP 1993) , to obtain roughly equivalent probability distributions of REF L .
‡ ‡ ‡ If such an adjustment is made, an REF L for solid tumors tends to be greater than the corresponding REF L for leukemias, as we have assumed on the basis of data for fission neutrons.
The lognormal distributions of REFs for 0.1-2 MeV neutrons assign a small probability to values less than 1.0, and all values in the piecewise-uniform probability distributions at lower and higher energies are greater than 1.0. However, REF could be less than 1.0 when the dose is delivered mainly by 2.2-MeV gamma rays emitted following capture of thermalized neutrons by 1 H nuclei, which could occur when the incident neutron energy is less than about 10 keV (NCRP 1971) . The possibility that REF is less than 1.0 at low energies is based on the consideration that the biological effectiveness of 2.2-MeV gamma rays could be somewhat less than that of reference 60 Co gamma rays used in radiobiological studies (Straume 1995) , which have an average energy of 1.25 MeV (ICRP 1983) . However, we have not taken this difference into account in estimating REFs for neutrons. The reduction in biological effectiveness of 2.2-MeV gamma rays relative to 60 Co gamma rays presumably is less than a factor of 2 (Straume 1995) , and this difference should be small compared with possible errors in estimating cancer risks that result from an assumption that the spectrum of photons to which Japanese atomic-bomb survivors were exposed has the same biological effectiveness as 60 Co gamma rays. That assumption is implicit in all REFs for neutrons and other radiation types presented in this paper.
We also acknowledge that probability distributions of REFs for neutrons could tend to overestimate cancer risks in humans at energies greater than about 0.1 MeV. In studies of fission neutrons in small mammals, a substantial fraction of the dose to target tissues was delivered by high-LET radiations (e.g., recoil protons). In humans, however, more of the dose to deep-lying tissues is delivered by gamma rays produced by neutron interactions in tissue. Therefore, RBEs obtained from studies in small mammals should tend to overestimate the biological effectiveness of incident fission neutrons in many organs and tissues of humans (ICRP 1996; Edwards 1997 Edwards , 1999 . However, we have not adjusted probability distributions of REFs for neutrons to account for this difference, mainly because it may depend in a complicated way on the target organ or tissue, neutron energy, and irradiation geometry (ICRP 1996) .
PROBABILITY DISTRIBUTIONS OF REFS FOR ALPHA PARTICLES
Approach to estimating REFs for alpha particles Like neutrons, alpha particles are presumed to have a linear dose-response for any stochastic endpoint at doses below those where significant cell killing occurs. Thus, in principle, it would be desirable to estimate risks of solid tumors in humans on the basis of estimates of RBE at high acute doses of high-energy gamma rays, RBE H , using the model in eqn (2), as we have done for neutrons, to lessen the influence of variations in DDREFs for low-LET reference radiations in radiobiological studies. The importance of DDREF is indicated, for example, by the pronounced increase in RBEs for bone cancers in dogs and mice with decreasing dose of alpha particles (NCRP 1990, Fig. 7.3) . As in studies of neutrons, high estimates of RBE at low doses, RBE M , may be due, at least in part, to high DDREFs for reference radiations.
As discussed below, however, most studies of the biological effectiveness of alpha particles did not use high-energy gamma rays at high acute doses as the reference radiation. Furthermore, an analysis to estimate RBEs of alpha particles at high acute doses, similar to the analysis for neutrons by Edwards (1997 Edwards ( , 1999 Alpha particles are simpler than neutrons in that the range of energies occurring in radioactive decay is limited and alpha particles of other energies usually are not encountered in exposures of workers and the public. A calculation of the effective quality factor (ICRU 1986, Fig. 5) indicates that the biological effectiveness of alpha particles is nearly independent of energy over the range of concern. Therefore, we assumed that probability distributions of REF L for solid tumors and leukemias apply to all alpha particles emitted by radionuclides.
REF for alpha particles and solid tumors
Studies of RBEs for alpha particles of potential relevance to induction of solid tumors in humans were reviewed by the NCRP (1990) and Muirhead et al. (1993) . Earlier studies were reviewed and analyzed by the ICRP (1991). A complicating factor in estimating RBEs is that the reference radiation often was not high-energy gamma rays. In some studies in mammalian cells, the reference radiation was x rays, and in studies of bone or lung tumors in mammals, the reference radiation usually was the continuous spectrum of beta particles emitted by 90 Sr and its decay product 90 Y, which has an average energy of 565 keV (ICRP 1983) , or other radionuclides. However, the difference between using high-energy beta particles or high-energy gamma rays as the reference radiation may not be significant, because studies discussed by the NCRP (1990) 226 Ra in inducing bone tumors in mice and dogs when toxicity is estimated on the basis of an average dose to the skeleton (NCRP 1990) . However, that difference is due mainly to deposition of radium and strontium throughout the volume of bone, in contrast to plutonium, which tends to remain on bone surfaces. Similar effects are seen in studies of other alpha-emitting radionuclides that deposit on bone surfaces (NCRP 1990) .
Estimates of RBE M for alpha particles and solid tumors obtained from reviews and analyses by the ICRP (1980), NCRP (1990) , and Muirhead et al. (1993) are summarized in Table 6 . Those estimates vary from about 5 to nearly 100 (see footnote b). On the basis of data in Table 6 and by taking into account that there is uncertainty in estimates of RBE M , we assume that REF L for alpha particles and solid tumors can be described by a lognormal probability distribution having a 95% confidence interval between 3 and 80. This distribution has a geometric mean of about 15 and geometric standard deviation of 2.3. A lognormal distribution was selected mainly on the basis of the variability in estimates of RBE M and the difficulty in judging a credible upper bound of possible values. Except in cases of exposure of the lung to short-lived decay products of radon in air (Land et al. 2003) , risks of solid tumors at low doses and low dose rates of alpha particles are estimated using the model in eqn (1).
In a previous analysis of selected data, including estimated risks of lung cancer in underground miners who were exposed to alpha-emitting radon decay products (NRC 1988) compared with estimated risks of lung cancer in Japanese atomic-bomb survivors who were exposed mainly to high-energy gamma rays (Shimizu et al. 1990 ), the U.S. Environmental Protection Agency (EPA) adopted a lognormal probability distribution of REF L for alpha particles and solid tumors (referred to as an "RBE") having a 90% confidence interval between 5 and 40 (U.S. EPA 1999). The 95% confidence interval of that distribution is about (4, 50). The lower confidence limit of 3 in our probability distribution is similar to the EPA's, except we assumed a slightly lower value to account for uncertainty in the lowest estimates of RBE M . The upper confidence limit of 80 in our probability distribution is substantially higher than the EPA's. Our assumption takes into account that several central estimates of RBE M in Table 6 are in the range of 20 -40 and that estimates for insoluble plutonium and lung cancer in mammals obtained by the ICRP (1980) include values in the range of about 60 -100. However, since such high estimates of RBE M for insoluble plutonium and lung cancer have not been seen in more recent studies summarized in Table 6 , we give only a small weight to values greater than 80. Grogan et al. (2000 Grogan et al. ( , 2001 Grogan et al. ( , 2002 developed separate probability distributions of REF L (also referred to as an "RBE") for alpha particles and lung, liver, and bone cancers. Lognormal probability distributions were assumed in each case, with a median and 95% confidence interval of 30 (9, 96) for lung cancer, 20 (8, 50) for liver cancer, and 40 (10, 156) for bone cancer. Those estimates for liver and bone cancer were based in part on estimated risks in medical patients who were administered Thorotrast compared with risks in Japanese atomic-bomb survivors. In comparison with our distribution of REF L for alpha particles and all solid tumors of 15 (3, 80), we give less weight to high values for lung and bone cancers, greater weight to high values for liver cancer, and greater weight to values less than 10 for all three cancers.
REF for alpha particles and leukemias
Risks of leukemias and related diseases are estimated using the model in eqn (4). In this study, an REF L for induction of leukemias by alpha particles was developed partly on the basis of data in humans. As discussed below, the data indicate that an REF L for leukemias should be substantially less than an REF L for solid tumors. However, we believe that interpretation of the data in humans is problematic, due probably to difficulties in separating the issue of estimating biological effectiveness from the issue of estimating absorbed doses to radiosensitive cells in bone marrow from alphaemitting radionuclides deposited in skeletal tissues.
Studies of medical patients who were administered Thorotrast, which is a colloidal form of thorium oxide, are a potentially important source of information on an REF L for alpha particles and leukemias. An REF L can be inferred by comparing estimated risks of leukemia in Thorotrast patients with an estimated risk of leukemia at low doses and low dose rates of gamma rays derived from data in Japanese atomic-bomb survivors and an assumed DDREF for gamma rays. Estimated lifetime risks of leukemia in Thorotrast patients range from 5 ϫ 10 Ϫ3 to 6 ϫ 10 Ϫ2 Gy Ϫ1 (Hunacek and Kathren 1995) . When compared with an estimated risk of 5 ϫ 10 Ϫ3 Gy
Ϫ1
at low doses and dose rates of gamma rays (U.S. EPA 1994), an REF L in the range of 1 to 12 is indicated. To account for uncertainties in estimated risks from exposure to alpha particles and gamma rays, we believe that the upper end of this range should be increased to about 15. In a previous study, the U.S. EPA (1999) used an estimated uncertainty in leukemia risks in Thorotrast patients (Grogan et al. 1999 ) and an estimated RBE of about 2 or 3 for induction of leukemias in mice by fission neutrons (Ullrich and Preston 1987) , which should be Table 6 . Estimates of RBE M for alpha particles obtained from reviews and analyses of selected studies by NCRP (1990) and Muirhead et al. (1993 Pr, or high-energy 60 Co gamma rays. b Range is based on analyses of dose-response at 10% and 40% lung tumor incidence from inhalation of soluble and insoluble alpha-emitting radionuclides combined; estimates based on analyses of lung tumor incidence from inhalation of insoluble 239 Pu oxide only are in the range of about 10 to about 60 -100 (ICRP 1980). c Value is based on re-analysis of preliminary data from Mays and Finkel (1980) . d Range is based on preliminary results from Boecker et al. (1988) and Griffith et al. (1987) ; value toward upper end of range is not supported by subsequent analysis by Hahn et al. (1991) , and value from Boecker et al. (1988) could be as low as 10. e Result is based on analysis of data from Boecker et al. (1988) and Griffith et al. (1987). similar to an RBE for alpha particles (Sinclair 1985; ICRU 1986) , to develop an "RBE" for alpha particles and leukemias in Thorotrast patients that is described by a lognormal probability distribution having a geometric mean of 3 and geometric standard deviation of 1.7. The 95% confidence interval of that distribution is (1.1, 8.5). In a similar analysis, Grogan et al. (2000 Grogan et al. ( , 2001 developed a lognormal probability distribution having a geometric mean of 3 and geometric standard deviation of 2.0. The 95% confidence interval of that distribution is (0.95, 9.5). The upper confidence limits of those two distributions are somewhat less than our assumed value.
It is questionable, however, whether an REF L for alpha particles and leukemias inferred from studies of Thorotrast patients applies to other forms of alphaemitting radionuclides (U.S. EPA 1994 EPA , 1999 . Most Thorotrast in skeletal tissues remains suspended in bone marrow, whereas more common forms of alpha-emitting radionuclides are deposited on bone surfaces and, in some cases, are distributed throughout the volume of bone. Thus, given the short range of alpha particles in tissue, Thorotrast may be substantially more effective in irradiating radiosensitive cells in bone marrow than other forms of alpha-emitting radionuclides.
An indication that an REF L for leukemias inferred from studies of Thorotrast patients may not apply to more common forms of alpha-emitting radionuclides is provided by studies of other populations, including radium dial painters who ingested 226 Ra and medical patients who were administered 224 Ra. When dosimetric models developed by the ICRP (1979) are used to estimate alpha dose to bone marrow from radium deposited in bone, an REF L substantially greater than unity, such as a central estimate of about 6 obtained from studies of Thorotrast patients (U.S. EPA 1994; Hunacek and Kathren 1995) , implies that leukemia risks in populations exposed to radium should be comparable to estimated risks of bone cancer (U.S. EPA 1999). However, an increase in leukemias in those populations has not been seen (NRC 1988) . For that reason, the U.S. EPA (1999) concluded that an "effective RBE" for leukemias from exposure to alpha emitters that deposit on bone surfaces or in the volume of bone can be described by a uniform probability distribution between 0 and 1. The EPA also emphasized, however, that this result does not imply that radiosensitive cells in bone marrow are less sensitive to alpha particles than to gamma rays. Rather, it probably reflects the highly nonuniform distribution of alpha dose in bone marrow when an alpha emitter is deposited on bone surfaces or in bone.
However, there also are difficulties in interpreting studies of leukemias in populations exposed to radium. The high doses of alpha particles in some cases may have resulted in substantial cell killing that masked any leukemia risk at lower doses. That possibility also has been noted in Thorotrast patients (Muirhead et al. 1993) . The observed incidence of leukemias in populations exposed to radium and the expected incidence in the absence of exposure both were low (about 10 cases or less). Therefore, there is considerable uncertainty in estimates of leukemia risk, and the data may not completely rule out the possibility of a significant risk. Finally, some leukemias in radium dial painters may have been missed as a result of incomplete information on the identification of those workers and their causes of death.
A third source of information on an REF L for alpha particles and leukemias in humans is data on RBE for fission neutrons and leukemias in mice. Such data are relevant because a large difference in biological effectiveness of alpha particles and fission neutrons is not expected and has not been observed (Sinclair 1985; ICRU 1986 ). As noted above, an estimated RBE for fission neutrons and leukemias in mice (Ullrich and Preston 1987 ) was used by the U.S. EPA (1999) to support an assumption about biological effectiveness that applies to Thorotrast patients and any other exposure situations involving alpha emitters suspended in bone marrow.
Given the variety of information on leukemia risks in humans exposed to alpha particles discussed above, some of which appears contradictory, we developed a probability distribution of REF L that gives some weight to all such information including (1) data in Thorotrast patients, (2) data in other populations exposed to alphaemitting radionuclides, and (3) data in mice exposed to fission neutrons. We also assume that there is only a small probability that alpha particles are less effective than high-energy gamma rays in inducing leukemias. Specifically, we describe REF L for alpha particles and leukemias by the following hybrid probability distribution:
1. 50% weight to a lognormal distribution having a 95% confidence interval between 1.0 and 15, based on estimates of leukemia risk in Thorotrast patients; 2. 25% weight to the value 1.0, based on the EPA's evaluation of leukemia risks in other populations and an assumption that REF L should not be less than 1.0; and 3. 25% weight to the lognormal probability distribution of REF L for fission neutrons and leukemias, which has a 95% confidence interval between 2.0 and 60 (see Table 5 ). This distribution has a median of 3.6 and 95% confidence interval of (1.0, 33).
Information on leukemia risks in populations exposed to radium discussed above suggests that the assumed probability distribution of REF L could result in substantial overestimates of risk to individuals who are exposed to common forms of alpha-emitting radionuclides that deposit on bone surfaces or in the volume of bone when alpha dose to bone marrow is estimated using dosimetric models developed by the ICRP (1979); i.e., an "effective" REF L in such cases may be less than unity (U.S. EPA 1999). However, we give little weight to an assumption that the biological effectiveness of alpha particles is less than that of high-energy gamma rays, mainly because we believe that possible errors in estimating alpha dose to radiosensitive cells in bone marrow should not be incorporated in a representation of biological effectiveness. We give some weight (25%) to an assumption that alpha particles and gamma rays are equally effective in inducing leukemias, but substantially more weight (75%) is given to an assumption that data in Thorotrast patients and RBEs for fission neutrons and leukemias in mice represent the biological effectiveness of alpha particles when radiosensitive cells in bone marrow are irradiated.
Correction for inverse dose-rate effect for alpha particles
As in the case of neutrons, an additional consideration in estimating cancer risks at low doses and dose rates of alpha particles is the possibility of an inverse dose-rate effect, whereby the biological effectiveness at a given dose increases as the dose rate decreases. An analysis of data on lung cancers in underground miners who were exposed to elevated levels of radon has shown an inverse dose-rate effect that could be as much as a factor of 3 but is more likely less than a factor 2 .
Reasonable arguments can be made both for and against the need to account for an inverse dose-rate effect in estimating cancer risks from chronic exposure to alpha particles. An argument in favor is that since an inverse dose-rate effect has been observed in some studies of neutrons, the effect, if it exists, should occur with other high-LET radiations. However, there are several counterarguments. First, an inverse dose-rate effect has not been observed in underground miners at exposures to shortlived alpha-emitting decay products of radon less than about 0.18 J h m Ϫ1 [50 Working Level Months (WLM)] .
§ § § Second, in contrast to studies of neutrons in small mammals, all studies of alpha-emitting radionuclides involved protracted exposures, and estimated RBEs may already account for an inverse doserate effect. Finally, since RBEs for alpha particles are extrapolated values at low doses and dose rates, RBE M , the highest values may be associated with the highest DDREFs for low-LET reference radiations and, thus, may result in overestimates of cancer risks in humans.
By considering the arguments summarized above and taking into account that all exposures to alpha particles emitted by radionuclides are chronic, we have assumed that the probability distributions of REF L for alpha particles and solid tumors or leukemias described previously should be modified by a small factor representing an inverse dose-rate effect, to be consistent with a similar assumption in cases of chronic exposure to neutrons. However, we give less weight to an inverse dose-rate effect for alpha particles than for neutrons, mainly on the basis of considerations that data in underground miners do not show an effect at low doses of concern in routine exposures of workers and the public ,**** and that the assumed probability distributions of REF L for alpha particles may already incorporate an inverse dose-rate effect when radiobiological studies used in our analysis involved protracted exposures and extrapolations of RBEs to low doses and dose rates. Specifically, we assume the discrete probability distribution for the enhancement factor representing an inverse dose-rate effect for alpha particles given in Table 7 . That distribution has an arithmetic mean of about 1.2.
Summary and discussion of REFs for alpha particles
Assumed probability distributions of REF L for alpha particles and solid tumors or leukemias and an enhancement factor to represent an inverse dose-rate effect, which is applied in all cases of exposure to alpha particles, are given in Table 7 . The geometric means and 95% confidence intervals of probability distributions of REF L modified by the enhancement factor are 18 (3.4, 100) for solid tumors and 4.1 (1.0, 42) for leukemias.
Determination of a representative probability distribution of REF L for alpha particles and leukemias is difficult, given the apparent contradictions in data in humans. The assumed probability distribution conforms to an expectation, based on studies of fission neutrons in mice and the similarity in effective quality factors for alpha particles and fission neutrons (ICRU 1986) , that REF L for leukemias should tend to be less than REF L for § § § An exposure to radon decay products of 0.18 J h m Ϫ1 (50 WLM) corresponds to an absorbed dose to the bronchial epithelium, where most lung carcinomas in underground miners were observed to originate, of about 0.8 Gy (ICRP 1987 (ICRP , 1993 . **** An analysis of risks of lung cancer from exposure to radon at lower levels found in homes has shown an increase in dose-response compared with data in underground miners (Field et al. 2000) , which may support an assumption of an inverse dose-rate effect at low doses.
solid tumors, and it gives some weight to all relevant data, including data which suggest that the effectiveness of alpha particles and high-energy gamma rays in inducing leukemias in humans is about the same.
However, the assumed probability distribution of REF L for leukemias could result in substantial overestimates of leukemia risks from exposure to common forms of alpha-emitting radionuclides that deposit on bone surfaces or in the volume of bone when absorbed doses to bone marrow are estimated using models developed by the ICRP. Our approach attempts to separate considerations of biological effectiveness of alpha particles from considerations of dosimetry. If there are difficulties with dosimetry models for alpha emitters in the skeleton, we do not believe they should be incorporated in assumptions about biological effectiveness.
PROBABILITY DISTRIBUTIONS OF REFS FOR PHOTONS

Approach to estimating REFs for photons
Compared with neutrons and alpha particles discussed previously and low-energy beta particles emitted by 3 H discussed later, there apparently have been few experimental studies of the biological effectiveness of x rays (or other lower-energy photons) in inducing stochastic effects relative to high-energy gamma rays. Furthermore, induction of dicentric chromosomes in human lymphocytes apparently is the only stochastic endpoint in mammalian systems that has been studied extensively in investigating the biological effectiveness of x rays at doses below those where cell killing could be important (NCRP 1990) . Nonetheless, we believe that data on chromosome aberrations, supplemented by information obtained from studies of other radiation types, support an assumption that lower-energy photons have a greater biological effectiveness than highenergy gamma rays at doses where only stochastic endpoints are important, † † † † in agreement with a previous conclusion by the ICRU (1986) .
Cancer risks in humans from exposure to x rays and other lower-energy photons are estimated using the model in eqns (1), (3), or (4), depending on cancer type and, for leukemias, on whether exposures are acute or chronic. At a given energy, the same REF at low doses and low dose rates, REF L , is used for all cancer types. This approach to risk estimation is based on assumptions that the dose-response for solid tumors or leukemias is linear or linear-quadratic, respectively, for photons of any energy, and that DDREF ␥ used in estimating risks of solid tumors is independent of energy. Given those assumptions, there is no advantage to deriving an REF for solid tumors at high doses and dose rates, REF H , for use in the model in eqn (2). Another complication that discourages that approach is that reference high-energy gamma rays and x rays often exhibit non-linear doseresponses in radiobiological studies. In many studies, DDREFs for those radiations differ substantially from each other and from the value of 2 normally assumed in radiation protection (ICRP 1991; NCRP 1993) , and they also vary from one study to another. An approach to risk estimation that uses an REF H is most appropriate when the dose-response for the radiation under study is linear at any dose and dose rate and DDREF for that radiation is unity. Thus, we focus on estimates of RBE for x rays at low doses and low dose rates, RBE M , and derivation of probability distributions of REF L on the basis of those data. † † † † The presence of a causal link between frequency of chromosome aberrations and induction of cancers in humans has been controversial, even though the two endpoints are positively correlated in some studies (Stram et al. 1993; Hagmar et al. 1998) . A study by Bonassi et al. (2000) supports the view that chromosome aberrations themselves are involved in the pathway to cancer, independent of an individual's history of exposure to carcinogens. c Risks of solid tumors from exposure to alpha particles are estimated using model in eqn (1), except in cases of exposure of the lung to alpha particles emitted by short-lived decay products of radon in air (Land et al. 2003) . d Risks of leukemias and related diseases from exposure to alpha particles are estimated using model in eqn (4).
REF based on estimated RBEs for x rays and data in humans
Studies of the effectiveness of 220 -250 kVp x rays in inducing dicentric chromosomes in human lymphocytes were analyzed by the NCRP (1990). The doseresponse for x rays and reference high-energy gamma rays was assumed to be of the form ␣D ϩ ␤D 2 , where D is the absorbed dose and ␣ and ␤ are coefficients given in Table 8 that were obtained from fits to the data. Table  8 also gives central estimates of RBE M at low doses, which were calculated as ␣ x /␣ ␥ using central estimates of the coefficients (NCRP 1990) , and 68% confidence intervals, which we calculated by assuming that reported central estimates and standard errors of ␣ x and ␣ ␥ define lognormal probability distributions of the coefficients and calculating probability distributions of RBE M as quotients of the distributions of ␣ x and ␣ ␥ using techniques of random sampling. We assume that estimates of RBE M for x rays and their uncertainties in Table 8 can be represented by a lognormal probability distribution having a 95% confidence interval between 1.0 and 6.5.
We also considered indirect information on the biological effectiveness of x rays that can be obtained from radiobiological studies in which the radiation under study was not x rays or gamma rays but both were used as reference radiations in studies of similar stochastic endpoints. The biological effectiveness of x rays can be estimated by comparing RBEs for the radiation under study relative to x rays with RBEs relative to gamma rays. Information obtained mainly from reviews of studies by experts is summarized in Table 9 . RBEs for life-shortening in mice (Upton et al. 1967 ), which was due primarily to leukemias, and tumor induction in rats (Wolf et al. 2000) should be especially relevant to estimating cancer risks in humans.
Indirect estimates of RBE for x rays in Table 9 suggest that a lognormal probability distribution of RBE M having a 95% confidence interval between 1.0 and 6.5 gives too much weight to higher values, even though uncertainties in those estimates undoubtedly are substantial. Furthermore, the highest estimate of RBE M in Table  8 has the largest uncertainty, which suggests that it should be given less weight than lower, less uncertain estimates for the same endpoint. On the basis of these considerations, we reduced the upper confidence limit of the lognormal probability distribution of RBE M obtained from the data in Table 8 from 6.5 to 5.0. The resulting lognormal probability distribution of RBE M is assumed to describe the data in Tables 8 and 9 . That distribution assigns a small weight (2.5%) to an assumption that the biological effectiveness of x rays and other lower-energy photons is the same as, or lower than, that of high-energy gamma rays, and the same weight is assigned to an assumption that values greater than 5.0 are possible. Neither assumption is ruled out by available data.
We then investigated whether information on the biological effectiveness of x rays relative to high-energy Table 8 . Dose-response for x rays and reference high-energy gamma rays for induction of dicentric chromosomes in human lymphocytes and estimates of RBE M . a Adapted from data presented by NCRP (1990, Tables 2.6 and 2.7). RBE M is RBE of x rays at low doses obtained by extrapolation of dose-responses for x rays and gamma rays. b Doses were delivered acutely or over time period of about 10 min or less. c ␣ and ␤ are coefficients of linear and quadratic terms in assumed linear-quadratic dose-response, respectively, and SE is standard error. d First entry is point estimate calculated by NCRP (1990) as ␣ x /␣ ␥ , and second entry in parentheses is 68% confidence interval calculated as described in text from standard errors in ␣ x and ␣ ␥ . e Data from Bauchinger (1984) . f Data from Fabry et al. (1985) . g Data from Lloyd et al. (1986) . h Data from Littlefield et al. (1989) . i Data for x rays from Brewen and Luippold (1971) , and data for gamma rays from Brewen et al. (1972) . j Data from Lloyd et al. (1975) .
gamma rays can be obtained from epidemiological studies. We first compared estimated risks of thyroid cancer in children exposed to x rays with estimated risks of thyroid cancer in Japanese atomic-bomb survivors who were exposed in childhood mainly to high-energy gamma rays. Central estimates and 95% confidence intervals of the excess relative risk (ERR) of thyroid cancer per Gy in children are given in Table 10 . An RBE for x rays can be estimated by assuming that the probability distribution of the estimated risk in each study group is lognormal and calculating quotients of probability distributions of risks from exposure to x rays and gamma rays using techniques of random sampling. Since average ages of children exposed to x rays were 7 y or less, we used the estimated risk in atomic-bomb survivors of age less than 10 y. The 95% confidence a Risk estimates from Ron et al. (1995) , except estimate for atomic-bomb survivors less than 10 y old at time of exposure is from Thompson et al. (1994) . b Central estimate and 95% confidence interval (in parentheses). c Pooled analysis includes data in atomic-bomb survivors. Risk estimate is dominated by data on childhood exposures to x rays at ages less than 10 y. intervals of RBEs obtained from the three studies of children exposed to x rays are (0.3, 4.2), (1.1, 9.2), and (0.06, 3.5), and the 95% confidence interval obtained from results of the pooled analysis is (0.2, 4.0). If we assume that the biological effectiveness of x rays should not be less than that of high-energy gamma rays, as indicated by the calculation shown in Fig. 1 , those confidence intervals suggest that an RBE for induction of thyroid cancer in children by x rays most likely is in the range of about 1-4. About the same range is indicated if estimates of excess absolute risk (EAR) per 10 4 person-y Gy in the study populations (Thompson et al. 1994; Ron et al. 1995) are used.
However, estimated risks in atomic-bomb survivors and other populations in Table 10 are sufficiently uncertain that they neither support nor refute an assumption that x rays are more effective than high-energy gamma rays in inducing thyroid cancer in children. An additional difficulty in estimating an RBE from those data is that exposures to x rays were fractionated but exposures of atomic-bomb survivors to gamma rays were acute. Thus, a significant RBE for x rays could be compensated by a DDREF greater than unity for those radiations (Land et al. 2003) . That is, risks from acute exposure of children to x rays could be about a factor of 2 higher than estimates in Table 10 . Such an increase would make it more likely that an RBE for x rays is greater than unity, but it still would not rule out the possibility that x rays and high-energy gamma rays are equally effective in inducing thyroid cancer in children.
Information on an RBE for x rays and thyroid cancer also can be obtained from a study of prepubescent rats exposed to x rays and beta particles emitted by 131 I (Lee et al. 1982) . As discussed later, the biological effectiveness of 131 I beta particles, which have an average energy of 182 keV (ICRP 1983) , should be similar to that of high-energy gamma rays. Central estimates and 95% confidence intervals of thyroid tumor incidence in rats from exposure to x rays relative to tumor incidence from exposure to 131 I beta particles at various mean thyroid doses obtained in the study are 1.1 (0.32, 3.7) at 0.8 Gy, 1.2 (0.43, 3.2) at 3.3 Gy, and 1.4 (0.24, 7.6) at 8.5 Gy. The average of those confidence intervals, which we calculated by giving equal weight to each result, is a distribution with a median and 95% confidence interval of 1.4 (0.6, 3.6). Thus, as in the comparison of risks of thyroid cancer in children exposed to x rays or highenergy gamma rays discussed above, this result is inconclusive on the question of whether x rays are more effective than 131 I beta particles in inducing thyroid cancer in the study animals, although an RBE as high as about 4 cannot be ruled out.
Finally, we examined results of epidemiological studies of cancer induction at other sites, including the colon, lung, skin, female breast, and bladder (UNSCEAR 2000) . Central estimates of the ERR per Gy and EAR per 10 4 person-y Gy in populations exposed to x rays more often than not are comparable to or less than central estimates of risks in atomic-bomb survivors of similar ages, although the lower risks from exposure to x rays in some cases may be due in part to the higher doses of x rays compared with doses of gamma rays in atomic-bomb survivors and the effect of a significant DDREF when doses of x rays are fractionated. In the relatively few cases where a higher risk from exposure to x rays is observed, which occurs most often when EARs are compared, the difference is as high as a factor of about 4 -6 and is about 3 on average. As in the other comparisons described above, however, uncertainties in estimated risks are sufficiently large that the data are inconclusive on the question of whether x rays are biologically more effective than high-energy gamma rays. ‡ ‡ ‡ ‡ Results of epidemiological studies described above can be summarized as follows. First, there is no evident difference in the effectiveness of x rays in inducing thyroid cancer compared with other cancers. Second, given the large uncertainties in epidemiological data and the possible importance of fractionation in exposures to x rays, an upper confidence limit of REF L for x rays as high as 5.0, as we have assumed on the basis of radiobiological data, cannot be ruled out. Finally, epidemiological data also do not rule out an assumption that x rays and high-energy gamma rays are equally effective in inducing cancers in humans.
On the basis of evidence obtained from radiobiological and epidemiological studies discussed above and an assumption that the biological effectiveness of x rays should not be substantially less than that of high-energy gamma rays, we describe REF L for orthovoltage x rays and other photons of similar energies by the following hydrid probability distribution: ‡ ‡ ‡ ‡ A more recent analysis of risks of breast cancer in eight study populations, including Japanese atomic-bomb survivors (Preston et al. 2002) , also is inconclusive. When estimated ERRs are compared, in no cases is the risk from exposure to x rays clearly greater than the risk in atomic-bomb survivors and, in most cases, the risk from exposure to x rays tends to be lower. In addition, estimated ERRs in populations that received protracted exposures to high-energy gamma rays at low dose rates are significantly less than the risk in atomic-bomb survivors (the 95% confidence intervals do not overlap) and, in all cases, ERRs from protracted exposure to gamma rays tend to be less than risks from exposure to x rays. When estimated EARs are compared, risks from exposure to x rays tend in most cases to be about a factor of 2-3 higher than the risk in atomic-bomb survivors, and risks from protracted exposure to high-energy gamma rays are comparable to risks in atomic-bomb survivors. However, uncertainties in EARs are much larger than uncertainties in ERRs in most cases, so it is difficult to draw conclusions from comparisons of EARs in different populations.
1. 75% weight to a lognormal distribution having a 95% confidence interval between 1.0 and 5.0 (geometric mean of 2.2), based on results of radiobiological studies; and 2. 25% weight to the value 1.0, based on the lack of clear evidence of a difference in biological effectiveness of x rays and high-energy gamma rays in epidemiological data.
Thus, we use the inconclusive results of epidemiological studies to modify the lognormal probability distribution developed on the basis of results of radiobiological studies by assigning a substantial weight to an assumption that orthovoltage x rays and other photons of similar energies have the same effectiveness as highenergy gamma rays in inducing cancers in humans. The assumed probability distribution of REF L has a median of 1.9 and 95% confidence interval of (1.0, 4.7). As discussed in the following section, this REF L is assumed to apply at photon energies of 30 -250 keV.
The weight to be given to an assumption that orthovoltage x rays and other photons of similar energies have the same biological effectiveness as high-energy gamma rays clearly is a matter of judgment and, thus, is somewhat arbitrary. By considering available data and their uncertainties, our judgment is that the weight given to that assumption should be substantial but should not be much higher than 25% (e.g., it should not be as high as 50%).
Energy dependence of REF for photons
In studies of the biological effectiveness of 220 -250 kVp x rays, most energies in the continuous spectra of photons were about 40 -100 keV (Stanton et al. 1979) . On the basis of the energy dependence of the effective quality factor shown in Fig. 1 , we assume that the probability distribution of REF L for orthovoltage x rays developed in the previous section applies at photon energies of 30 -250 keV. The effective quality factor is essentially independent of energy over much of that range and is approximately twice the value at the average energy of 60 Co gamma rays of 1.25 MeV. An assumption that this REF L applies at energies as low as 30 keV is supported by calculations of the biological effectiveness of 60 kVp and 80 kVp x rays relative to gamma rays from the Hiroshima and Nagasaki atomic bombs (Brenner 1999) .
The effective quality factor shown in Fig. 1 also indicates that the biological effectiveness of photons should increase as the energy decreases below 30 keV. For example, on the basis of the calculation in Fig. 1 , Brenner and Amols (1989) estimated that 23 kVp x rays should be about 1.3 times more effective than 44 -250 kVp x rays in inducing breast cancer. On that basis, we assume that the probability distribution of REF L for 30 -250 keV photons should be increased at energies less than 30 keV. We represent this increase by a multiplicative factor that is assumed to be independent of energy and is described by a triangular probability distribution having a lower bound of 1.0, a mode of 1.3, and an upper bound of 1.6. The resulting probability distribution of REF L at photon energies less than 30 keV has a median of 2.4 and 95% confidence interval of (1.1, 6.1). § § § §
Summary and discussion of REFs for photons
The biological effectiveness of lower-energy photons in inducing cancers in humans relative to highenergy gamma rays is assumed to be independent of dose and dose rate under similar conditions of exposure to the two radiations. The assumed probability distributions of REF L at different photon energies are summarized in Table 11 .
The assumed probability distribution of REF L for 30 -250 keV photons is based mainly on radiobiological studies of 220 -250 kVp x rays, which show a clear increase in biological effectiveness compared with highenergy gamma rays, and a calculation of the energy dependence of the effective quality factor (ICRU 1986) . § § § § Recent radiobiological studies support an assumed increase in biological effectiveness at photon energies less than 30 keV. Studies of stochastic endpoints discussed by indicate that RBE M for 25-30 kVp x rays is about 4 relative to 200 kVp x rays and about 8 relative to 60 Co gamma rays, and Frankenberg-Schwager et al. (2002) reported RBEs for mutagenic effects of about 2.4 -2.7 for x rays of similar energies relative to orthovoltage x rays. Those estimates suggest that REF L for low-energy photons could be higher than we have assumed. Schmid (2002) estimated somewhat lower RBE M s for induction of dicentric chromosomes in human lymphocytes by 29 kVp x rays of 1.6 Ϯ 0.3 relative to 220 kVp x rays and 4.8 Ϯ 1.7 and 6.1 Ϯ 2.5 relative to 60 Co gamma rays. Heyes and Mill (2004) (1), and risks of leukemias and related diseases under conditions of acute or chronic exposure to photons at any dose are estimated using model in eqn (3) or (4), respectively.
Although most radiobiological studies did not investigate cancer endpoints, there is indirect evidence from studies of life-shortening in mice and tumor induction in rats that an REF for induction of cancers by such x rays could be as high as about 3. Epidemiological data on cancer risks in particular organs or tissues, especially risks of thyroid cancer in children, are inconclusive on the question of whether orthovoltage x rays are biologically more effective than high-energy gamma rays, due to large uncertainties in the data. By considering all radiobiological and epidemiological evidence, we give an appreciable weight (25%) to an assumption that orthovoltage x rays and high-energy gamma rays are equally effective in inducing cancers in humans. The assumed increase in biological effectiveness at photon energies less than 30 keV relative to orthovoltage x rays was based on calculations but is supported by recent radiobiological data.
PROBABILITY DISTRIBUTIONS OF REFS FOR ELECTRONS
With the exception of low-energy electrons emitted in beta decay of 3 H, we are not aware of any studies of the biological effectiveness of electrons in inducing stochastic effects relative to high-energy gamma rays or x rays. In this section, we develop a probability distribution of REF L for 3 H beta particles, which have an average energy of 5.7 keV and a maximum energy of 18.6 keV (ICRP 1983) . We then consider the biological effectiveness of higher-energy electrons and low-energy Auger electrons.
REF for tritium beta particles
Many studies have indicated that beta particles emitted in 3 H decay are more effective than high-energy gamma rays in inducing stochastic effects (NCRP 1990; Straume and Carsten 1993) . Estimates of RBE for stochastic endpoints obtained in studies reviewed by Straume and Carsten (1993) , including studies in which the reference radiation was x rays, are summarized in Table 12 . For the purpose of developing an REF L for 3 H beta particles that is consistent with assumed REFs for other radiation types, the most relevant studies are those in which the reference radiation was gamma rays. In most such studies, the reference radiation was delivered chronically to match conditions of exposure to 3 H beta particles. Thus, cancer risks in humans from exposure to 3 H beta particles are estimated using the model in eqn (1) or (4), depending on cancer type. If we assume that DDREF for 3 H beta particles in the various studies is about the same as DDREF for the reference radiation, RBEs obtained under conditions of chronic exposure in Table 12 are estimates of RBE M .
On the basis of data obtained under conditions of chronic or subacute exposure to gamma rays in Table 12 , central estimates of RBE M are in the range of about a Summary of estimates from selected studies given by Straume and Carsten (1993, Tables 1-4) . b RBEs for tritium in form of tritiated thymidine are omitted. This compound, if it is not catabolized, is taken up only by nuclei of cells that synthesize DNA, in contrast to other forms of tritium encountered in the workplace or environment, including tritiated organic compounds that are metabolic precursors, which usually are distributed throughout soft tissues (ICRP 1989a) . c Data from Gragtmans et al. (1984) , Yamaguchi et al. (1985) , Little (1986) , Suzuki et al. (1989) , Yokoro et al. (1989) , and Johnson (1990, 1991) . Endpoints studied include tumors in mice and rats, leukemia in mice, and transformation in mouse and hamster cells. d Data from Carsten and Commerford (1976) , Ueno et al. (1982) , UNSCEAR (1982) , Searle (1984) , Kashima et al. (1985) , Matsuda et al. (1985) , Nakamura et al. (1985) , Suyama and Etoh (1985) , Xiang-yan et al. (1986) , Chopra and Heddle (1988) , Byrne and Lee (1989) , Nomura and Yamamoto (1989) , Ueno et al. (1989) , and Kamiguchi et al. (1990) . Endpoints studied include 6-thioguanine resistance in mouse cells in vitro; chromosome aberrations in human sperm and fish lymphocytes in vitro and in mouse zygotes, lymphocytes, and spermatogonia; micronuclei in mammalian cells; mutations in Drosophila spermatozoa and in mice in vivo; specific locus mutations in male mice; and dominant lethals in male and female mice. e Data from Lloyd et al. (1975) , Bocian et al. (1977) as refit by Prosser et al. (1983) , Prosser et al. (1983) , Vulpis (1984) , Lloyd et al. (1988) , and Morimoto et al. (1989) . f Data from Yamada et al. (1982) and Satow et al. (1989) . Endpoints studied include two-cell to blastocyte in mouse embryo in vitro and teratogenic effects in rat embryos. Tables  1-3) . If a nominal biological effectiveness of x rays relative to high-energy gamma rays of 2 is assumed on the basis of the probability distribution of REF L for orthovoltage x rays developed in the previous section, those data suggest that RBE M for 3 H beta particles relative to gamma rays delivered chronically could be as high as about 4 -6.
By taking into account estimates of RBE M in Table  12 and the biological effectiveness of x rays relative to gamma rays noted above, we assume that REF L for 3 H beta particles can be described by a lognormal probability distribution having a 95% confidence interval between 1.2 and 5.0. This distribution has a geometric mean of 2.4 and geometric standard deviation of 1.4. The upper tail of the distribution represents an assumption that REF L could be 5 or greater, and that a reasonable upper bound cannot be determined with certainty. The small probability assigned to an REF L greater than 4 (about 10%) also is intended to take into account that RBEs for organically-bound tritium appear to be 2-3 times higher than RBEs for HTO or 3 H incorporated into amino acids (Straume and Carsten 1993) . That is a relevant consideration when some HTO taken into the body becomes organically bound before it is excreted (ICRP 1989a; Straume and Carsten 1993) . On the basis of discussions in the following sections and except as noted therein, the probability distribution of REF L for 3 H beta particles is assumed to apply to electrons of energy less than 15 keV.
Analyses of uncertainty in the biological effectiveness of 3 H beta particles were reported previously by Hamby (1999) and Harrison et al. (2002) . On the basis of studies using HTO, Hamby (1999) described the biological effectiveness of 3 H beta particles relative to highenergy gamma rays by a piecewise-uniform probability distribution between 1.0 and 3.5, and on the basis of studies of HTO and organically-bound forms, Harrison et al. (2002) assumed a uniform probability distribution between 1.0 and 2.5. The latter analysis differs from ours in that RBEs relative to high-energy gamma rays or lower-energy x rays were considered together without taking into account the likelihood that x rays have a greater biological effectiveness. As noted above, an assumption that RBEs for 3 H beta particles relative to x rays should be increased by a factor of about 2 results in a median and upper confidence limit in our probability distribution of REF L that are substantially higher than values assumed by Harrison et al. (2002) .
In addition, the previous analyses assumed that the biological effectiveness of 3 H beta particles relative to gamma rays does not exceed 3.5 (Hamby 1999) or 2.5 (Harrison et al. 2002) . In contrast, we believe that data on RBE are consistent with an assumption that REF L could be as high as about 5, and that an upper bound near 5 cannot be established with certainty.
The assumed lognormal probability distribution of REF L for 3 H beta particles having a median of 2.4 and 95% confidence interval of (1.2, 5.0) is similar to the assumed probability distribution of REF L for photons of energy less than 30 keV developed in the previous section, which has a median of 2.4 and 95% confidence interval of (1.1, 6.1). Such a consistency is expected when, as discussed below, energies of electrons that deliver an absorbed dose are similar for the two radiation types.
Consideration of energy dependence of REF for electrons
Since 3 H beta particles have very low energies, we considered whether electrons of higher energy also should have an REF L greater than unity. A study of thyroid cancer in rats induced by x rays and 131 I beta particles (Lee et al. 1982) discussed previously is the only study we are aware of that was designed to investigate the biological effectiveness of higher-energy electrons. In the absence of radiobiological data, we addressed this question in the following way.
In the previous section, the energy dependence of the effective quality factor shown in Fig. 1 and data on the biological effectiveness of x rays were used to develop probability distributions of REF L with a median greater than 1.0 for photons of energy less than 250 keV. Since the dose from irradiation by photons is due almost entirely to ionization produced by energetic secondary electrons, an REF for photons of a given energy represents the biological effectiveness of secondary electrons produced by first interactions of those photons in tissue.
Information on the relative importance of Compton scattering and the photoelectric effect in tissue as a function of photon energy (NCRP 1991, Fig. A.1; Shleien et al. 1998, Table 5.2 and Figs. 5.1 and 5.2) , maximum and average energies of the continuous spectrum of secondary electrons produced by Compton scattering of incident photons of a given energy (Turner 1995, Table 8 .1), and energies of secondary electrons produced by the photoelectric effect in tissue (Shleien et al. 1998, Table 8 .5) leads to the following conclusions (Kocher et al. 2002) . First, the biological effectiveness of electrons of energy greater than about 60 keV, which is the average energy of Compton electrons produced by 250 keV photons, should be about the same as that of high-energy gamma rays. Second, the biological effectiveness of 15-60 keV electrons should be about the same as that of 30 -250 keV photons. Third, the biological effectiveness of electrons of energy less than 15 keV, with the possible exception of Auger electrons discussed in the following section, should be similar to that of photons of energy less than 30 keV.
On the basis of the analysis described above, we assume that the probability distribution of REF L for 3 H beta particles applies to electrons of energy less than 15 keV. In cases of exposure to beta-emitting radionuclides, this REF L should be applied when the average energy of the continuous spectrum of beta particles is less than 15 keV. Use of the average energy of beta particles is reasonable when an argument to assume an REF L greater than unity at energies less than 15 keV is based in part on the average energy of the continuous spectrum of secondary electrons produced by Compton scattering of photons of a given energy. Application of this REF L to low-energy Auger electrons is discussed in the following section.
However, we have not adopted an REF L greater than unity for 15-60 keV electrons, even though their biological effectiveness should be similar to that of 30 -250 keV photons. This decision was based on two considerations noted previously. The first is the lack of data on RBEs for 15-60 keV electrons. Second, the assumed REF L for 30 -250 keV photons is based on studies in which the energies of most x rays were about 40 -100 keV (Stanton et al. 1979) , and an assumption that RBEs for such x rays apply at higher photon energies up to 250 keV was based on the calculated energy dependence of the effective quality factor in Fig. 1 . Thus, adoption of an REF L greater than unity for 15-60 keV electrons would be based in large part on two assumptions for which there apparently is no experimental evidence. In general, we developed probability distributions of REFs for particular radiation types only when they can be supported by radiobiological or epidemiological data.
Biological effectiveness of Auger electrons
Radionuclides that emit Auger electrons require special consideration, because of the very low energies of those radiations [often a few keV or less (ICRP 1983) ], their high intensities [often greater than one per decay (ICRP 1983) ], their short range in tissue [less than 0.1 m (Shleien et al. 1998, Fig. 5.8.1)] , and the tendency of some Auger emitters to incorporate into DNA (ICRP 1991) . Limited data on the biological effectiveness of Auger electrons are summarized by the ICRP (1991, paragraph B67 3 H beta particles, there are potentially important uncertainties that are difficult to address including, for example, the fraction of the activity deposited in an organ or tissue that is incorporated into DNA, the dependence of RBE on the energy of Auger electrons, and the dependence of RBE on dose when cell killing could occur. Thus, we concur with a recommendation by the ICRP (1991) and NCRP (1993) that the biological effectiveness of Auger emitters incorporated into DNA should be handled as special cases using techniques of microdosimetry.
Summary and discussion of REFs for electrons
The assumed probability distributions of REF L for electrons are given in Table 13 . The biological effectiveness of low-energy electrons relative to high-energy gamma rays is assumed to be independent of dose and dose rate under similar conditions of exposure to both radiations.
Acute exposure to beta particles and other electrons emitted by inhaled or ingested radionuclides is not expected to be of concern. For example, since the residence half-time of tritiated water in soft tissues is 10 d or more (ICRP 1989a), exposures to 3 H beta particles generally should be chronic. Acute exposure to electrons should occur only in cases of accidental external exposure, and only higher-energy electrons are of concern in such cases.
The assumed probability distribution of REF L for electrons of energy less than 15 keV is potentially important in calculating cancer risks and probability of causation whenever intakes of radionuclides that emit low-energy beta particles, internal conversion electrons, 
SUMMARY OF REFS FOR ALL RADIATION TYPES
On the basis of evaluations of data on the biological effectiveness of neutrons, alpha particles, lower-energy photons, and lower-energy electrons relative to highenergy 60 Co gamma rays, we have developed radiation effectiveness factors (REFs) for those radiations for use in estimating cancer risks and probability of causation of radiogenic cancers in identified individuals. REFs are analogous to, but distinct from, quality factors and radiation weighting factors used in radiation protection. REFs developed in this work are being used in the compensation program for workers at DOE facilities who develop cancers (NIOSH 2002) and in evaluating claims for compensation for cancers by veterans of military services who participated in the atmospheric nuclearweapons testing program (Mather and Otchin 2004) .
REFs developed in this work are expressed as probability distributions that are intended to provide subjective representations of uncertainty in the biological effectiveness of different radiation types in inducing cancers in humans. Probability distributions of REFs were developed by taking into account uncertainties in data on RBE obtained from radiobiological studies of various stochastic endpoints, data on cancer risks from exposure to different radiation types obtained from epidemiological studies, and other judgments involved in evaluating the applicability of available information to cancer induction in humans.
Assumed probability distributions of REFs for the different radiation types considered in this work are given in Tables 5, 7 , 11, and 13. Additional summaries in Tables 14  and 15 give the 50th percentile (median) and 95% confidence interval (2.5th and 97.5th percentiles) in each case. Those summaries facilitate comparisons of REFs for different radiation types, provided the difference between an REF H for neutrons and solid tumors at high acute doses and the other REFs, which are REF L s that apply at low doses and low dose rates, is taken into account. For purposes of such comparisons, probability distributions of REF H could be multiplied by the probability distribution of DDREF ␥ for breast and thyroid cancer or for all other solid tumors incorporated in IREP (Land et al. 2003) or, more approximately, by the DDREF ␥ of 2 normally assumed in radiation protection (ICRP 1991; NCRP 1993) .
DISCUSSION AND NEEDS FOR FURTHER WORK
The work discussed in this paper was compelled by the need to develop methods of estimating probability of causation of radiogenic cancers that give individuals who file claims for compensation for cancers the benefit of the doubt (DHHS 2002; NRC 2003) . Thus, uncertainties in all parameters, including parameters that represent the biological effectiveness of different radiation types, must be taken into account explicitly in estimating an upper confidence limit of probability of causation.
As far as we are aware, this work provides the first comprehensive assessment of uncertainties in data on biological effectiveness of relevance to estimating cancer risks and probability of causation associated with exposure to many radiation types often encountered in the workplace or the environment. Uncertainties in biological effectiveness of various radiation types have been evaluated in other studies discussed in this paper (Edwards 1997 (Edwards , 1999 U.S. EPA 1999; Hamby 1999; Grogan et al. 2000 Grogan et al. , 2001 Grogan et al. , 2002 Harrison et al. 2002) . However, each of those studies Table 11 ). However, probability distribution of REF L with median greater than unity for 15-60 keV electrons is not adopted, due to lack of supporting radiobiological data. d Probability distribution of REF L is based on data on RBE for 3 H beta particles and applies when average energy of beta particles or energy of discrete internal conversion or Auger electrons is less than 15 keV, except distribution does not apply to Auger-emitting radionuclides incorporated into DNA.
considered only a single radiation type. Furthermore, although experts have reviewed and evaluated extensive sets of data on RBEs (ICRP 1980; ICRU 1986; NCRP 1990; Muirhead et al. 1993; Straume and Carsten 1993; Edwards 1997 Edwards , 1999 , those evaluations often did not focus on addressing uncertainties in RBEs, and they sometimes were concerned primarily with developing point estimates of quantities related to biological effectiveness for use in radiation protection, rather than quantities that would be most appropriate for use in estimating cancer risks and probability of causation of radiogenic cancers in identified individuals.
We acknowledge that there could be important concerns about our analysis and the resulting subjective probability distributions of REFs. Some of these concerns, which may indicate needs for further work, are described as follows. Table 7 and apply to alpha particles of any energy emitted by radionuclides; all probability distributions include enhancement factor to represent inverse dose-rate effect. Table 13 , footnote c). g Auger-emitting radionuclides incorporated into DNA are excluded. Beta particles emitted in decay of radionuclides are included if average energy of continuous spectrum is less than 15 keV.
A concern in developing REFs for neutrons is the scarcity of data on RBEs at energies outside the range of about 0.1-2 MeV, which encompasses the energies of most fission neutrons. For example, reviews by the NCRP (1990) and Edwards (1997 Edwards ( , 1999 did not include any data at the lowest (Ͻ 10 keV) and highest (Ͼ 20 MeV) energies. As a result, we relied on a step-function representation of the radiation weighting factor (w R ) developed by the ICRP (1991) for use in radiation protection (see Table 1 ) to indicate reductions in central estimates (medians) of REFs at energies outside the range of 0.1-2 MeV, and that assumption is open to question. Furthermore, assumed probability distributions of REFs at energies outside that range are bounded, in contrast to an assumption of unbounded lognormal distributions at energies of 0.1-2 MeV. An assumption of bounded distributions in those cases was driven primarily by the difficulty in developing smooth unbounded distributions that have the desired relationships between an upper confidence limit and the median, but it is difficult to argue that those REFs could not possibly be less than unity or greater than the specified upper bounds.
Further investigation into the existence of an inverse dose-rate effect under conditions of chronic exposure to neutrons at low doses also could be important, because an assumption of a small effect increases upper confidence limits of assumed REFs and, therefore, estimated upper confidence limits of probability of causation. Finally, although we support an approach to estimating risks of solid tumors from exposure to neutrons at any dose and dose rate based on probability distributions of REF H that are developed from estimated RBEs at high doses and dose rates of reference high-energy gamma rays (CIRRPC 1995; Edwards 1997 Edwards , 1999 , that approach has not gained widespread acceptance. Further investigation into methods of estimating such RBEs when the dose-response for the reference radiation is non-linear could be useful.
The most important concern with REFs for alpha particles involves the development of a representative probability distribution of REF L for induction of leukemias. Relevant data in humans and animals do not present a consistent picture of biological effectiveness in this case, and data in humans appear to indicate that the biological effectiveness of alpha particles emitted by common forms of radionuclides could be substantially less than that of high-energy photons, contrary to expectations and estimates of leukemia risk in Thorotrast patients. An apparently low biological effectiveness of alpha particles emitted by common forms of radionuclides could be due, in part, to errors in estimating alpha dose to radiosensitive tissues in bone marrow when a radionuclide is deposited on bone surfaces or in the volume of bone. Therefore, we developed a probability distribution of REF L for alpha particles and leukemias on the basis of an assumption that the issue of estimating biological effectiveness should be separated from issues of dosimetry. However, our approach is not entirely satisfactory, even though it takes different types of data on RBE into account, because, as long as existing dosimetry models are used, it appears that risks of leukemia from exposure to bone-seeking alpha-emitting radionuclides could be overestimated substantially at an upper limit of confidence. Further studies clearly are desirable, given the potential importance of exposure to bone-seeking alpha emitters in the workplace and the environment and the high excess relative risk (ERR) of leukemias at a given absorbed dose to bone marrow compared with ERRs for many other cancers (Land et al. 2003) .
Further evaluations of RBEs for alpha particles and solid tumors at low doses, RBE M , with the aim of investigating a credible upper confidence limit of REF L , also could be useful, given the potential importance of that upper confidence limit in estimating upper confidence limits of probability of causation. Finally, as in the case of neutrons, further investigation into whether a correction to represent an inverse dose-rate should be applied to REF L s for alpha particles could be important in estimating upper confidence limits of probability of causation.
There are several possible concerns about our analysis for photons. Radiobiological data on the effectiveness of orthovoltage (180 -250 keV) x rays relative to high-energy gamma rays apparently are obtained mainly from studies of induction of chromosome aberrations in human lymphocytes. Since an assumption that chromosome aberrations are indicative of an increased risk of cancer is not without controversy and epidemiological studies have not clearly indicated whether or not x rays are more effective than high-energy gamma rays in inducing cancers in humans, additional studies of the biological effectiveness of x rays in inducing cancers in animals are of interest. However, further analyses of epidemiological data on cancer risks in specific organs or tissues may not be fruitful, given the large uncertainties in the data and the possibility that a significant increase in biological effectiveness of x rays is largely compensated by a DDREF greater than unity, especially under conditions of protracted exposure.
Another concern is our assumption, which is based on a calculation of the effective quality factor shown in Fig. 1 , that photons of energy up to 250 keV have the same biological effectiveness relative to higher-energy photons as orthovoltage x rays. However, the energy dependence of Q is based on a defined relationship between the quality factor and lineal energy in a 1-m diameter sphere (ICRU 1986, Fig. 2 ) that may not apply in larger tissue volumes. We also used the calculation in Fig. 1 to infer a further increase in biological effectiveness at photon energies less than 30 keV. Recent data on RBEs for such low-energy photons should be evaluated, given that there are data that indicate that their biological effectiveness could be higher than we have assumed. The possibility that REF L has a significant energy dependence below 30 keV also should be investigated.
The main issue in developing REFs for electrons is whether electrons of intermediate energies in the range of about 15-60 keV are biologically more effective than high-energy gamma rays. Our arguments that this should be the case are based on the assumed REF L for 30 -250 keV photons and the energies of secondary electrons produced by interactions of photons of those energies in tissue. However, we are not aware of any supporting radiobiological data.
The energy dependence of REF L at electron energies less than about 15 keV also should be investigated, given that a calculation of the effective quality factor for photons shown in Fig. 1 suggests that REF L for lowenergy photons increases with decreasing energy. Such an investigation could be conducted using low-energy x rays, because the dose from those radiations is delivered mainly by low-energy electrons produced by the photoelectric effect (NCRP 1991, Fig. A.1; Shleien et al. 1998 ,  Table 5 .2 and Figs. 5.1 and 5.2). Data on the biological effectiveness of electrons of energy on the order of 1 keV could be particularly important in cases of exposure to radionuclides that emit high intensities of low-energy Auger electrons.
We also note two general concerns about our analysis. One is the question of whether RBEs at low doses and dose rates, RBE M , derived from radiobiological studies are influenced by an assumption of a linear or linear-quadratic dose-response and, if so, by how much. This could be an important concern when assumed probability distributions of REF L are based in large part on estimates of RBE M obtained by extrapolation of observed responses at higher doses and dose rates. A second concern is that our analysis was based in large part on reviews and evaluations of available data by experts, and it is possible that relevant data sets were not included in those reviews or that those evaluations were biased in some way.
If we look beyond the specific purpose of this work, which was to provide assumptions about biological effectiveness for use in compensation programs, we hope that it will prompt further considerations including, for example, debates on the issue of how uncertainties in biological effectiveness of different radiation types should be taken into account in radiation protection as well as assessments of risk to human health.
